<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04256785</url>
  </required_header>
  <id_info>
    <org_study_id>FMS-VSL3-19</org_study_id>
    <nct_id>NCT04256785</nct_id>
  </id_info>
  <brief_title>Probiotic VSL#3 for the Treatment of Gastrointestinal Symptoms Associated to Fibromyalgia</brief_title>
  <official_title>Efficacy and Tolerability of the Probiotic VSL#3 for the Treatment of Patients With Fibromyalgia and Associated Gastrointestinal Symptomatology: a Randomized, Double-blind Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elena Pita Calandre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Actial Farmaceutica S.r.l.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidad de Granada</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluated the efficacy and tolerability of probiotic VSL#3 for the treatment of
      gastrointestinal symptoms in patients with fibromyalgia; 50% of the participants will receive
      probiotic and the remaining 50% will receive matching placebo in a double-blind, randomized
      design.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Many patients with fibromyalgia experience associated gastrointestinal symptomatology such as
      abdominal pain, abdominal bloating, meteorism, diarrhea and/or constipation. To date there is
      not any specific treatment for these symptoms that markedly impair the quality of life of
      these subjects. This trial intends to investigate if the addition of a polymicrobial
      probiotic product, which has shown efficacy in patients with irritable bowel syndrome, can
      also be useful to ameliorate the gastrointestinal symptomatology of patients with
      fibromyalgia.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 11, 2018</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastrointestinal symptoms</measure>
    <time_frame>baseline, one, two, three, four, eight and twelve weeks after treatment</time_frame>
    <description>change in the self-reported mean severity of the three more relevant gastrointestinal symptoms measured in a 0-10 visual analog scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fibromyalgia Impact Questionnaire Revised (FIQR)</measure>
    <time_frame>baseline, four, eight and twelve weeks after treatment</time_frame>
    <description>change in the self-reported questionnaire that evaluates the severity of fibromyalgia symptomatology in a scale ranging from 0 to 100 points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insomnia Severity Inventory (ISI)</measure>
    <time_frame>baseline, four, eight and twelve weeks after treatment</time_frame>
    <description>change in the self-reported questionnaire evaluating the sleep disturbances in a scale ranging from 0 to 28 points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>9-item Patient Health Questionnaire (PHQ-9)</measure>
    <time_frame>baseline, four, eight and twelve weeks after treatment</time_frame>
    <description>change in th e self-reported questionnaire evaluating the severity of depression in a scale ranging from 0 to 27 points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-Form Health Survey SF-36</measure>
    <time_frame>four, eight and twelve weeks after treatment</time_frame>
    <description>baseline, change in the self-reported questionnaire evaluating the general health quality in a scale ranging from 0 to 100 points</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Fibromyalgia</condition>
  <condition>Gastrointestinal Disease</condition>
  <arm_group>
    <arm_group_label>VSL#3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>probiotic VSL#3, 2 sachets b.i.d for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matched placebo, 2 sachets b.i.d for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>VSL#3</intervention_name>
    <description>sachets containing probiotic</description>
    <arm_group_label>VSL#3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>sachets containing placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosed of fibromyalagia

          -  experiencing at least 3 chronic gastrointestinal symptoms

          -  signed informed consent to participate

          -  accept to not change previously prescribed treatment during study duration

        Exclusion Criteria:

          -  mental illness excepting depression

          -  severe organic disease

          -  additional gastrointestinal disease excepting irritable bowel syndrome

          -  pregnancy

          -  breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena P. Calandre, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad de Granada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto de Neurociencias &quot;Federico Oloriz&quot;</name>
      <address>
        <city>Granada</city>
        <zip>18012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Yunus MB. The prevalence of fibromyalgia in other chronic pain conditions. Pain Res Treat. 2012;2012:584573. doi: 10.1155/2012/584573. Epub 2011 Nov 17.</citation>
    <PMID>22191024</PMID>
  </results_reference>
  <results_reference>
    <citation>Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RL, Mease PJ, Russell AS, Russell IJ, Walitt B. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016 Dec;46(3):319-329. doi: 10.1016/j.semarthrit.2016.08.012. Epub 2016 Aug 30.</citation>
    <PMID>27916278</PMID>
  </results_reference>
  <results_reference>
    <citation>Slim M, Calandre EP, Rico-Villademoros F. An insight into the gastrointestinal component of fibromyalgia: clinical manifestations and potential underlying mechanisms. Rheumatol Int. 2015 Mar;35(3):433-44. doi: 10.1007/s00296-014-3109-9. Epub 2014 Aug 14. Review.</citation>
    <PMID>25119830</PMID>
  </results_reference>
  <results_reference>
    <citation>Arranz LI, Canela MÁ, Rafecas M. Dietary aspects in fibromyalgia patients: results of a survey on food awareness, allergies, and nutritional supplementation. Rheumatol Int. 2012 Sep;32(9):2615-21. doi: 10.1007/s00296-011-2010-z. Epub 2011 Jul 22.</citation>
    <PMID>21833524</PMID>
  </results_reference>
  <results_reference>
    <citation>Bull MJ, Plummer NT. Part 2: Treatments for Chronic Gastrointestinal Disease and Gut Dysbiosis. Integr Med (Encinitas). 2015 Feb;14(1):25-33. Review.</citation>
    <PMID>26770128</PMID>
  </results_reference>
  <results_reference>
    <citation>Ford AC, Harris LA, Lacy BE, Quigley EMM, Moayyedi P. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther. 2018 Nov;48(10):1044-1060. doi: 10.1111/apt.15001. Epub 2018 Oct 8.</citation>
    <PMID>30294792</PMID>
  </results_reference>
  <results_reference>
    <citation>Kim HJ, Vazquez Roque MI, Camilleri M, Stephens D, Burton DD, Baxter K, Thomforde G, Zinsmeister AR. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil. 2005 Oct;17(5):687-96.</citation>
    <PMID>16185307</PMID>
  </results_reference>
  <results_reference>
    <citation>Guandalini S, Magazzù G, Chiaro A, La Balestra V, Di Nardo G, Gopalan S, Sibal A, Romano C, Canani RB, Lionetti P, Setty M. VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study. J Pediatr Gastroenterol Nutr. 2010 Jul;51(1):24-30. doi: 10.1097/MPG.0b013e3181ca4d95.</citation>
    <PMID>20453678</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 2, 2020</study_first_submitted>
  <study_first_submitted_qc>February 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>February 4, 2020</last_update_submitted>
  <last_update_submitted_qc>February 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Universidad de Granada</investigator_affiliation>
    <investigator_full_name>Elena Pita Calandre</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>probiotic</keyword>
  <keyword>efficacy</keyword>
  <keyword>tolerability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data for all primary and secondary outcomes will be made available</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>One year after study completion</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by study sponsor and P.I.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

